AbSci focuses on improving protein expression and biomanufacturing in the biotech industry. Its main product is an advanced protein expression platform that uses a semi-oxidizing cytoplasm and a dual inducible promoter system, allowing for better control over protein production rates. This results in higher quality and more efficient drug manufacturing. A key feature of AbSci's offerings is SoluPure, a method that simplifies protein purification without chromatography, speeding up the production process and reducing costs. AbSci's workflow can create cell lines that produce active proteins in as little as three months, which is much faster than traditional methods. Unlike its competitors, AbSci aims to replace older mammalian expression systems with its more efficient solutions. The company's goal is to enhance drug discovery and manufacturing processes for pharmaceutical and biotech companies, ultimately transforming the production of biologics.